Background
Phase 3, open-label, 4-arm randomized controlled trial (GAIA/CLL13; German CLL Study Group). N=926 fit treatment-naive CLL patients (CIRS ≤6, CrCl ≥70 mL/min; TP53/del17p excluded). Randomized 1:1:1:1 to chemoimmunotherapy (CIT) vs venetoclax-rituximab (VenRit) vs venetoclax-obinutuzumab (VenObi) vs venetoclax-ibrutinib (VenIbr). Designed to establish superiority of fixed-duration venetoclax-based regimens over CIT in fit patients.
Interventions and follow up
Arm A: Chemoimmunotherapy (CIT): investigator's choice FCR (fludarabine+cyclophosphamide+rituximab, 6 cycles) or BR (bendamustine+rituximab, 6 cycles) [N=229]
Arm B: VenRit: venetoclax 400 mg/d (ramp-up) + rituximab 375/500 mg/m², 12 cycles fixed-duration [N=237]
Arm C: VenObi: venetoclax ramp-up → 12 cycles + obinutuzumab 1000 mg d1/8/15 cycle 1 then d1 cycles 2–6 [N=229]
Arm D: VenIbr: venetoclax + ibrutinib 420 mg/d continuous [N=229]
Primary endpoint: Undetectable MRD in peripheral blood at 15 months AND PFS
Median follow-up: 38.8 months (primary)
Arm B: VenRit: venetoclax 400 mg/d (ramp-up) + rituximab 375/500 mg/m², 12 cycles fixed-duration [N=237]
Arm C: VenObi: venetoclax ramp-up → 12 cycles + obinutuzumab 1000 mg d1/8/15 cycle 1 then d1 cycles 2–6 [N=229]
Arm D: VenIbr: venetoclax + ibrutinib 420 mg/d continuous [N=229]
Primary endpoint: Undetectable MRD in peripheral blood at 15 months AND PFS
Median follow-up: 38.8 months (primary)
Results
uMRD rate (PB, 15 mo): CIT 52.0%, VenRit 57.0%, VenObi 86.5%, VenIbr 92.2%
PFS HR vs CIT: VenIbr 0.32 (P<.001), VenObi 0.42 (P<.001), VenRit 0.79 (not significant)
3-yr PFS: CIT 75.5%, VenRit 80.8%, VenObi 90.5%, VenIbr 90.9%
OS: No significant differences among arms at primary analysis
PFS HR vs CIT: VenIbr 0.32 (P<.001), VenObi 0.42 (P<.001), VenRit 0.79 (not significant)
3-yr PFS: CIT 75.5%, VenRit 80.8%, VenObi 90.5%, VenIbr 90.9%
OS: No significant differences among arms at primary analysis
Adverse events
Hematologic: Grade ≥3 neutropenia: CIT 51.9%, VenObi 41.7%, VenIbr 22.3%
Cardiovascular: AFib grade ≥3 7.2% in the VenIbr arm (ibrutinib component)
Infections: Grade ≥3 infections highest with VenIbr (21.2%) and CIT
Other: Obinutuzumab infusion reactions grade ≥3 ~5%; treatment discontinuation for toxicity highest in CIT arm
Cardiovascular: AFib grade ≥3 7.2% in the VenIbr arm (ibrutinib component)
Infections: Grade ≥3 infections highest with VenIbr (21.2%) and CIT
Other: Obinutuzumab infusion reactions grade ≥3 ~5%; treatment discontinuation for toxicity highest in CIT arm
Conclusions
In fit treatment-naive CLL, VenObi and VenIbr significantly improved uMRD rates and PFS over CIT, with the triplet VenIbr achieving the highest uMRD (92.2%). VenObi offered the best balance of efficacy and tolerability among fixed-duration options; VenRit did not significantly improve PFS over CIT. No OS benefit was established at primary analysis.
Key Limitations
TP53/del(17p) patients were excluded, limiting generalizability. VenIbr contains continuous ibrutinib through cycle 15 with MRD-guided extension, partially diluting the fixed-duration advantage. At primary analysis (38 months) OS data remain immature. VenRit, despite FDA approval in R/R disease (MURANO), showed only modest improvement over CIT in fit frontline CLL. Obinutuzumab adds infusion reaction and neutropenia risk versus rituximab.
Clinical Context
CLL13/GAIA established VenObi (venetoclax-obinutuzumab) and VenIbr as superior to CIT in fit CLL. In CLL17, VenO, VenI, and continuous ibrutinib were non-inferior to each other at ~3-year follow-up. For treatment-naive fit CLL, VenObi (fixed-duration, 12 months, per CLL14) is an FDA-approved standard. VenIbr remains investigational. FCR/BR are reserved for young IGHV-mutated patients seeking long-term remissions. ESMO-MCBS: 4 (VenObi for TN-CLL based on CLL14/CLL13).